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ABSTRACT
Introduction: The REGAL (RSV evidence—a
geographical archive of the literature) series
provide a comprehensive review of the
published evidence in the field of respiratory
syncytial virus (RSV) in Western countries over
the last 20 years. This third publication covers
the risk and burden of RSV infection in infants
with chronic lung disease (CLD), formerly
called bronchopulmonary dysplasia (BPD).
Methods: A systematic review was undertaken
of publications between January 1, 1995 and
December 31, 2015 across PubMed, Embase,
The Cochrane Library, and Clinicaltrials.gov.
Studies reporting data for hospital visits/
admissions for RSV infection among infants
with CLD/BPD who were not prophylaxed, as
well as studies reporting RSV-associated
morbidity, mortality, and healthcare costs,
were included. Burdens of disease data were
compared with preterm infants without CLD/
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BPD, other high-risk groups and term infants.
Study quality and strength of evidence (SOE)
were graded using recognized criteria.
Results: A total of 1837 studies were identified
and 39 were included. CLD/BPD is a significant
independent risk factor for RSV hospitalization
[RSVH (odds ratio 2.2–7.2); high SOE]. Infants
and young children with CLD/BPD had high
RSVH rates which were generally similar in
Europe, the United States, and Canada, mostly
varying between 12 and 21%. Infants with CLD
also had a longer length of hospital stay than
other high-risk groups and term infants (high
SOE). On average, infants spent 4–11 days in
hospital (moderate SOE). Once hospitalized for
RSV, affected children were at risk for a more
severe course of disease than children with no
RSVH (moderate SOE).
Conclusion: Severe RSV infection in infants
and young children with CLD/BPD poses a
significant health burden in Western
countries. Further studies focussing on the
burden of RSV infection in this
well-recognized population at high risk for
severe disease are needed to help improve








Respiratory syncytial virus (RSV) is the most
important cause of severe respiratory infection
in infants, accounting for over 3 million
hospitalizations worldwide each year [1].
Chronic lung disease (CLD) [formerly called
bronchopulmonary dysplasia (BPD)] is the most
common pulmonary complication of
premature birth and increases the risk of RSV
infection because it compromises lung
function, distorts airway architecture, and
promotes a pro-inflammatory milieu [2, 3].
Severe RSV infection is associated with
substantial morbidity and constitutes a
considerable burden on healthcare systems [4].
During the first 2 years of life, children with
CLD/BPD are hospitalized for severe RSV at a
higher rate than children born at term or more
than 36 weeks gestational age (wGA) [5–7].
High-risk infants, including those with CLD/
BPD, also have a significantly higher intensive
care unit (ICU) admission rate and length of
stay (LOS) in hospital, and require more
invasive and longer respiratory support than
near-term or full-term infants [8]. There is
currently no curative treatment for RSV
infection. Treatment focuses primarily on
supportive measures, such as providing
supplemental oxygen and ensuring adequate
hydration. RSV immunoprophylaxis is the
mainstay of disease prevention and is
indicated for specific children at high risk of
developing serious disease. Current published
guidelines recommend that RSV
immunoprophylaxis is offered to infants with
CLD/BPD who require medical therapy, such as
supplemental oxygen, bronchodilator, diuretic
or chronic corticosteroid treatment, within
6 months before the onset of the RSV season
[9–15].
New RSV therapeutics are currently being
developed [16]. Therefore, it is important that
there is a greater understanding of CLD/BPD as
a condition leading to enhanced risk for severe
RSV disease in order to improve preventative
and management strategies, improve overall
patient outcomes, and reduce the burden on
healthcare systems. To provide a
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comprehensive understanding of severe RSV
disease in Western societies, a panel of experts
in RSV from the United States, Canada and
Europe undertook an evidence-based search of
the literature which has accumulated over the
past two decades. REGAL (RSV Evidence—a
Geographical Archive of the Literature) defines
the current state of the art in our understanding
of RSV as well as, importantly, identifying gaps
in our knowledge and future areas of research.
This paper, which represents the third in a series
of seven publications covering a range of topics
on RSV disease, identifies and describes the risks
and associated morbidity and mortality of
severe RSV infection requiring hospitalization




REGAL addresses seven specific research
questions, covering: overall epidemiology,
prematurity, CLD/BPD, congenital heart
disease (CHD), long-term respiratory
morbidity, other high-risk groups (e.g. Down
syndrome), and prevention, management and
future perspectives. The systematic reviews
undertaken to answer each research question
all use the same broad methodology, which has
been described elsewhere [17]. The full protocol
and generic search terms for the systematic
reviews are available as part of the online
supplement. In brief, a systematic and
comprehensive search of the medical literature
electronically indexed in PubMed, EMBASE, the
Cochrane Library and clinicaltrials.gov was
conducted. The detailed search strategy used
free-text search terms combined with Medical
Subject Headings (MeSH). As per the ambit of
REGAL, only studies conducted in Western
countries were included, which we defined as
the United States, Canada, and Europe
(including Turkey and the Russian Federation).
Literature Search
In this systematic literature review, we sought
to answer the key question: ‘‘What is the
morbidity, long-term sequelae and mortality of
infants and young children with CLD/BPD due
to severe RSV lower respiratory tract infection?’’
The search for this systematic review
included studies conducted in children
B18 years old and published between January
1, 1995 and December 31, 2015. The target
population was infants and young children
with CLD/BPD who had ‘proven’ or ‘probable’
RSV and had or had not received RSV
immunoprophylaxis. We retained only studies
that reported RSV hospitalization (RSVH) and
outcome data for infants and young children
with CLD/BPD. However, studies with mixed
pediatric populations hospitalized with RSV
were also considered if there were sufficient
data on infants and young children with CLD/
BPD. We limited publications by excluding
meta-analyses and review articles. No language
limits were set on the database searches, with
the caveat that English translations of at least
the abstract had to be available.
The following general terms and limits were
used in MEDLINE (PubMed), EMBASE and the
Cochrane Library: ‘‘RSV’’ OR ‘‘respiratory
syncytial virus’’ AND ‘‘lower respiratory tract
infection’’ OR ‘‘bronchiolitis’’ OR ‘‘pneumonia’’
AND ‘‘chronic lung disease’’ OR ‘‘CLD’’ OR
‘‘bronchopulmonary dysplasia’’ OR ‘‘BPD’’ AND
‘‘hospitalization’’ OR ‘‘predisposition’’ OR ‘‘risk
factor’’ AND ‘‘limits: human, child (birth to
18 years)’’. The search results were
supplemented by a review of the
bibliographies of key articles for additional
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studies and inclusion of relevant abstracts
presented at key meetings. Other significant
studies of the target population, published
during the drafting of the manuscript, were
also included in the review, as identified by the
authors. Two reviewers (Smith and Blake)
undertook the search, with any disagreements
resolved after discussion with a third reviewer
(Rodgers-Gray) and Carbonell-Estrany. All
authors reviewed the search results, made any
additions and amendments, and approved the
final list of studies for inclusion.
Definition of CLD/BPD
It is recognized that the working definitions of
CLD and BPD have evolved over recent years,
now targeting extremely preterm infants with
structurally immature lungs and pulmonary
vasculature due to a predominant arrest of
lung growth as ‘‘new BPD’’ in contrast to the
‘‘original BPD’’ based on the Northway
classification [18–23]. Since studies involving
RSV do not uniformly include a definition of
CLD/BPD, for completeness all reports
describing infants with CLD/BPD were
considered for inclusion in this review in order
to elucidate the additional risk of RSV infection
in infants with respiratory issues at birth. In
general terms, we defined BPD in infants born at
\32 weeks post-menstrual age as follows, based
on established criteria [24]:
– Mild BPD: oxygen requirement for the first
28 days but in room air at 36 weeks
post-menstrual age
– Moderate BPD: oxygen requirement for the
first 28 days and oxygen \30% at 36 weeks
post-menstrual age
– Severe BPD: oxygen requirement for the first
28 days and oxygen [30% or continuous
positive airway pressure (CPAP) or
mechanical ventilation at 36 weeks
post-menstrual age.
For infants born [32 weeks post-menstrual
age, the definition was adjusted for the time
endpoint of 56 days of life instead of 36 weeks
post-menstrual age [25]. CLD was defined as the
continuous need for oxygen or respiratory
support beyond 36 weeks post-menstrual age.
Outcomes of Interest
The outcomes of interest for this review
included hospitalization rates due to severe
RSV infection, hospital LOS, ICU admission
and LOS, oxygen requirement, need for and
duration of mechanical ventilation and/or
non-invasive ventilation, and case-fatality
rates.
Evaluation of Data
Included publications were graded according to
the Oxford Centre for Evidence-Based Medicine
Levels of Evidence [26, 27]: level 1 evidence
[local and current random sample surveys (or
censuses)]; level 2 evidence (systematic review
of surveys that allow matching to local
circumstances); level 3 evidence (local
non-random sample); and level 4 evidence
(case-series). For each study, we also conducted
a risk of bias assessment using the RTI Item
Bank (score of 1 = very high risk of bias; score of
12 = very low risk of bias) for observational
studies [28].
Statement of Ethics Compliance
The analysis in this article is based on
previously published studies and does not
involve any new studies of human subjects
performed by any of the authors.
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RESULTS AND DISCUSSION
Articles Selected
From the initial literature search, we identified
2422 potentially relevant articles, of which 592
were duplicates (Fig. 1). After phase 1 screening
of the titles, 215 articles were considered and
reviewed at abstract level, while 183 abstracts
were rejected for not meeting the selection
criteria, the majority because the studies did not
focus on the population of interest (children
B18 years old in Western countries) or disease
of interest (RSV burden or hospitalization).
Thirty-nine studies were included of which 32
were identified from the literature search and an
additional 7 from reference lists/other sources.
Data extraction tables for all 39 studies,
including evidence grades and risk of bias
assessments can be found in the online
supplement.
Incidence of RSV Hospitalization
Studies from the United States, Canada and
Europe have shown that infants with CLD/BPD,
particularly those born prematurely, are at high
risk for RSV-associated hospitalizations in the
first 2 years of life [5, 29–46]. Across a number of
studies, CLD/BPD had the highest or, in one
case, the second highest, odds ratio (OR) of all
independently significant risk factors for RSVH
(Table 1). In a retrospective cohort study of
1721 premature infants [23–36 weeks
gestational age (wGA)], CLD, defined as
C28 days of perinatal oxygen, was found to be
Fig. 1 PRISMA ﬂow diagram. Epidemiology and burden of RSVH in infants with CLD/BPD. The third reviewer (B.R.G.)
and X.C.E. were not required to resolve any disagreements during the review process
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a significant risk factor for RSVH (OR 3.7;
P\0.001 vs. those who required \28 days of
oxygen) [32]. Similarly, in a population-based
cohort study of 1103 infants born \35 wGA,
CLD, defined as oxygen requirement beyond
36 weeks post-conceptual age, was found to be
independently associated with RSVH [adjusted
OR 3.99, 95 % confidence interval (CI) 1.4–11.2]
[31]. When restricted to studies using a
definition of ‘a continued need for oxygen
therapy at 36 weeks post-conceptual age’, the
OR for RSVH was 2.2–3.99. Overall, studies
report ORs of between 2.2 and 7.2 for CLD/
BPD as a risk factor for RSVH.
The reported incidence of RSVH in infants
and young children with CLD/BPD who had
not received RSV immunoprophylaxis varies
between 12 and 46%, with 8 of 10 studies
reporting an incidence of between 12 and 21%
(Table 2) [6, 31, 32, 36, 41, 48–52]. In the
Munich RSV study, the risk of RSVH was
higher in preterm infants (B35 wGA) with
CLD compared with preterm infants (B35
wGA) without CLD (15.0% vs. 4.4%) [31].
Taken together and discounting any
heterogeneity across study populations, the
average, weighted incidence of RSVH among
895 children with BPD/CLD in the identified
studies (Table 2) was 16.8%. When limited to
studies with a definition of BPD/CLD as ‘a
continued need for oxygen at 36 wGA’, the
weighted mean was also 16.8%.
During the first 2 years of life, children with
CLD/BPD are hospitalized for severe RSV at a
higher rate than children born at term (C36
wGA) [5–7]. There is also some evidence that
children with CLD/BPD have higher RSVH rates
than those with CHD [7] or preterm infants
without comorbidities [5, 7]. In a retrospective
cohort study of all children \3 years old
enrolled in the Tennessee Medicaid program
from July 1989 through June 1993 (248,652
child-years), the estimated RSVH rate per 1000
children in the first and second year of life was
higher for those with BPD compared with other
high-risk populations (Table 3) [7]. A
population-based cohort study performed in
the UK also reported higher RSVH rates during
the first year of life among infants with CLD
[56.2 per 1000 infants (95% CI 49.9–63.2)]
compared with those born prematurely [47.3
per 1000 infants (95% CI 44.4–50.2)] and those
born at term [22.4 per 1000 infants (95% CI
21.8–22.9)] [5]. In contrast, a Finnish study [6]
showed that whilst significantly higher RSVH
rates were reported for children with CLD than
for children born at [36 wGA without CLD
(12.0% vs. 1.9%; P = 0.003), differences in the
admission rates between children with CLD and
those born at B35 wGA were not significant.
Comparing rates observed in various studies,
particularly in children with CLD/BPD, is
extremely difficult because of differences in
methodology and the demographics of the
study populations.
Data suggest that RSVH rates for infants with
CLD/BPD have steadily decreased over the past
15 years [42, 53]. Findings from an 11-year
cohort study (1998–2008) conducted in the US
suggest that RSVH in children aged \2 years
with CLD have steadily decreased even while
all-cause hospitalizations in this high-risk
population remained unchanged [53]. On
average, about 966 hospitalizations for RSV
(range 98–1373) per year were reported for
children aged \2 years with CLD. Over the
study period, the predicted rate of RSVH
decreased significantly, by 48% (from 93.78 to
49.06 per 1 million children; P = 0.013). The
authors suggest reasons for this decrease may
460 Infect Dis Ther (2016) 5:453–471


















Clinical diagnosis of BPD requiring
ongoing medical treatment (i.e.
supplemental oxygen, steroids,
bronchodilators, or diuretics









Continued need for oxygen therapy






Continued need for oxygen therapy
at 36 weeks post-menstrual age or
if children\2 years required
medical therapy within 6 months






Oxygen dependency at 28 days after
birth
26 46.2
Liese 2003 [31] Germany Preterm infants
\35 wGA
Continued need for oxygen therapy






Continued need for oxygen therapy






Continued need for oxygen therapy






Oxygen dependency beyond 28 days
after birth
235 19.1
Thomas 2000 [51] UK Preterm infants
\32 wGA
Continued need for oxygen therapy
at 36 weeks post-conceptual age
34 8.8
Joffe 1999 [32] US Preterm infants
B36 wGA
Oxygen therapy for C28 days in the
NICU
124 14.5
BPD bronchopulmonary dysplasia, CLD chronic lung disease, NICU neonatal intensive care unit, RSV respiratory syncytial
virus, wGA weeks gestational age
a Study also included infants born B35 wGA and B6 months old
b Study included infants born C36 wGA, but all infants with CLD born B35 wGA
c Placebo group with BPD
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include improved neonatal intensive care unit
(NICU) and outpatient management of CLD,
and possibly increased use of RSV
immunoprophylaxis in this high-risk
population [53].
Morbidity and Healthcare Resource
Utilization
Studies have demonstrated that hospitalization
due to RSV infection among infants with CLD/
BPD not only leads to an increased risk of
morbidity but also increased healthcare
resource utilization, including admission to
NICU, oxygen supplementation, and
mechanical ventilation
[8, 30, 38, 41, 51, 54–59]. The typical length of
stay in hospital for RSV infection for infants
with CLD/BPD is 4–11 days compared to
2–5 days in premature or term infants without
CLD/BPD (Table 4) [38, 41, 51, 57, 58].
Multivariate analyses have shown CLD/BPD to
be significantly and independently associated
with a complicated course of disease and use
and duration of mechanical ventilation [54, 55].
BPD (oxygen dependency beyond 28 days) has
been associated with a requirement for
extracorporeal membrane oxygenation
(ECMO) support (OR 11.8, 95% CI 2.2–63.1;
P = 0.004) [54].
Data from the Canadian PICNIC (Pediatric
Investigators Collaborative Network on
Infections in Canada) study [60] showed that
there were no significant differences among
infants with BPD and those with other
pulmonary disorders (cystic fibrosis, recurrent
aspiration pneumonitis, pulmonary
malformation, neurogenic disorders interfering
with pulmonary toilet, and tracheoesophageal
fistula) for the morbidity measures: duration of
hospitalization, ICU admission, duration of ICU
stay, mechanical ventilation and duration of
mechanical ventilation (overall hospitalization
rate: 91 for infants with BPD vs. 68 for infants
with other pulmonary disorders). However, the
relatively small sample sizes of the respective
sub-populations may have influenced the
findings [60].
Greenough et al. [50] reported that preterm
infants with CLD who require hospitalization
for RSV infection have significantly greater
morbidity in the first 2 years after birth than
Table 3 RSV hospitalization rates for high-risk populations [7]
Group RSV hospitalization rate per 1000 children
First year of life Second year of life
BPD 388 73
CHD 92 18
B28 wGA 70 30
29 to\33 wGA 66 8
33 to\36 wGA 57 11
Term (with no underlying medical condition) 30 4
Data are from a retrospective cohort study of all children\3 years old enrolled in the Tennessee Medicaid program from
July 1989 through June 1993 (248,652 child-years)
BPD bronchopulmonary dysplasia, CHD congenital heart disease, RSV respiratory syncytial virus, wGA weeks gestational
age
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those without RSV infection. In this
retrospective study, 235 preterm infants (\32
wGA) who were admitted to NICU during the
first week after their birth and subsequently
developed CLD (defined as an oxygen
dependency beyond 28 days after birth) were
followed until they were 2 years of age.
Forty-five infants (19 %) had at least one
hospital admission for a proven RSV infection.
Compared with preterm infants (\32 wGA)
with CLD/BPD with probable bronchiolitis and
those with other respiratory problems, preterm
infants with CLD/BPD and proven RSV
infection had a longer length of stay in
hospital (median: 21 vs. 6.5 and 8 days,
respectively; P\0.001) and longer duration of
stay in pediatric wards (median 16 vs. 4.5 and
6 days, respectively). Outpatient attendances
per infant during the first 2 years of life were
also significantly higher in the RSV proven
group (P\0.01), as were primary care
consultations for respiratory illnesses (P\0.05)
compared with the other groups [50]. Findings
from a subsequent retrospective study of 190 of
the original cohort of 235 children with CLD,
published in 2004, showed that children who
had been hospitalized with a proven RSV
infection in the first 2 years required more
health care for respiratory problems in years
2–4 inclusive [61].
These retrospective studies demonstrate that
severe RSV infection in preterm children with
CLD/BPD causes considerable morbidity, as
indicated by their significantly higher use of
health care resources compared to full-term
children hospitalized for RSV infection
[38, 41, 50, 51, 57, 58, 61]. However, too few
data are available on infants with CLD/BPD
admitted to NICU to allow more detailed
conclusions to be drawn. This highlights the
need for more studies specifically considering
severe RSV infection in infants with CLD/BPD,
as the majority of data in this high-risk group
come from mixed populations of previously
healthy children and preterm infants with and
without CLD/BPD.
Healthcare Costs
Data from the published literature show that
RSVH in preterm infants with CLD is associated
with substantial healthcare costs [4, 50, 61, 62].
In the 2001 retrospective study by Greenough
et al. [50], preterm infants with CLD who had a
proven RSV infection generated significantly
higher costs of care, approximately three times
those who were RSV-negative. In the
subsequent study, published in 2004, costs
were assessed over a 3-year period when the
children were aged 2–4 years [61]. Compared
with the non-RSVH group, these infants
continued to incur significantly greater costs
of care for respiratory problems in later
childhood [median £2630 (€4000, US $4800),
range £124–18,091 vs. £1360 (€2500, US $3000),
range £5–18,929] [61]. In a population-based
cohort study of 3458 infants and children
hospitalized for severe RSV infection during
the RSV seasons 1996–1997 to 1999–2000 in the
Netherlands, RSVH costs were higher for infants
with BPD (€5785) than for other high-risk
groups, including those with lower gestational
age (€5555), and lower birth weight (€3895).
The authors observed that the differences in
RSVH costs were mainly due to a longer
duration of hospitalization [4]. Similarly, an
observational, retrospective survey in Spain that
analysed all RSVHs for children up to 5 years of
age reported during the 1997–2011 period
found that the average LOS and hospital costs
Infect Dis Ther (2016) 5:453–471 465
were significantly higher in high-risk children,
including those with BPD [62].
Estimates of RSVH costs have been reported
in other studies, but these were not
differentiated by patient characteristics such as
CLD/BPD, making comparisons difficult.
Case-Fatality Rates
Few studies in the published literature on RSVH
report case-fatality rates in infants with CLD/
BPD, and therefore it is difficult to ascertain
from the available data the precise number of
true RSV deaths in this high-risk population.
There are currently no data to suggest that
case-fatality rates are higher in those children
with CLD/BPD than in healthy term children or
premature children without CLD/BPD
[38, 51, 58, 63, 64].
LIMITATIONS
There are two main limitations that merit
consideration. First, the changing definitions
of CLD/BPD over time may have affected the
cross-comparisons that were generated between
studies. Second, there was a lack of studies
specifically investigating CLD/BPD. The
majority of the studies identified comprised
mixed populations, a proportion of which had
CLD/BPD. In addition, other factors, such as
improvements in medical practice over time
and the type of RSV testing and surveillance
systems employed will have influenced
interpretation of the results. New studies
should recognize that the established criteria
for the definition of BPD [24, 65] may be used as
a framework but are in a state of evolution
[18, 22, 66] and, ideally, should include control
for prematurity (stratified by gestational age) as
another well-recognized risk factor for RSVH.
This will enable more meaningful comparisons
between studies and thereby a more reliable
assessment of the true burden of RSV infection
in this at-risk population.
CONCLUSIONS
This review has assessed, quantified and
summarized all the key evidence for the
burden of RSV infection in infants and young
children with CLD/BPD in Western countries
over the last 20 years. Data show that this
specific population are particularly susceptible
to developing severe RSV disease necessitating
re-hospitalization and medical therapy,
including supplemental oxygen and
mechanical ventilation, following discharge
from NICUs. Data suggest that the course of
illness is more severe in children with CLD/BPD
compared with otherwise healthy preterm
infants and is associated with longer duration
of hospital stay. Rates of RSVH among this
high-risk group in European countries appear to
be generally similar to those in the United
States and Canada.
This systematic review provides further
evidence that severe RSV infections in infants
and young children with CLD/BPD still pose a
significant health burden in Western countries.
Most of our knowledge, however, has come
from studies conducted more than a decade
ago. These findings highlight the need for
more up-to-date studies of the relative
importance of CLD/BPD as a risk factor for
severe RSV disease. Improved surveillance of
this population will provide a more
informative insight into the burden of disease
to help improve outcomes and plan allocation
of health care resources.
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Key statements/ﬁndings Level of evidencea
CLD/BPD is a highly
signiﬁcant independent risk
factor for RSVH (OR
2.2–7.2)
Level 1 (level 1 studies: n = 2;
risk of biasb: 11.0)
CLD/BPD has been associated
with a higher rate of RSVH
than other high-risk groups
(e.g. CHD, preterm without
comorbidities) and term
infants
Level 1 (level 1 studies: n = 3;
risk of biasb: 10.7)
The reported incidence of
RSVH in infants and young
children with CLD/BPD
who have not received RSV
immunoprophylaxis mostly
varies between 12 and 21%
Level 1 (level 1 studies: n = 3;
risk of biasb: 10.7)
Median stay in hospital for
RSV infection in children
with CLD/BPD is 4–11
days
Level 1–2 (level 1 studies:
n = 1; level 2 studies:
n = 2; risk of biasb: 10.7)
CLD/BPD is signiﬁcantly and
independently associated
with a complicated course of




Level 1–3 (level 1 studies:
n = 1; level 3 studies:
n = 1; risk of biasb: 10.0)
Key areas for research
More up-to-date research and speciﬁc studies are needed on the
burden of severe RSV infection in infants and young children
with CLD/BPD
Comparison of the morbidity and mortality incurred by infants
with ‘‘OLD’’ versus ‘‘NEW’’ CLD/BPD
BPD bronchopulmonary dysplasia, CHD congenital heart disease,
CLD chronic lung disease, ECMO extracorporeal membrane
oxygenation, LOS length of stay, OR odds ratio, RSVH
respiratory syncytial virus hospitalization
a Level 1: Local and current random sample surveys (or
censuses); level 2: Systematic review of surveys that allow
matching to local circumstances; level 3: Local non-random
sample; level 4: case-series [26, 27]
b Average RTI Item Bank Score [28], where 1 = very high risk
of bias and 12 = very low risk of bias
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